NCT01176461 2023-01-18
Multiple Class I Peptides & Montanide ISA 51 VG w Escalating Doses of Anti-PD-1 ab BMS936558
H. Lee Moffitt Cancer Center and Research Institute
Phase 1 Completed
Clinical Trials
8 trialsNCT00470015 2019-02-19
Vaccine Therapy and GM-CSF With or Without Low-Dose Aldesleukin in Treating Patients With Stage II, Stage III, or Stage IV Melanoma
Mayo Clinic
Phase 1 Completed
NCT00091338 2015-04-30
Interleukin-7 and Vaccine Therapy in Treating Patients With Metastatic Melanoma
National Cancer Institute (NCI)
Phase 1 Completed
NCT00005841 2014-05-22
Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma
University of Southern California
Phase 1 Terminated
NCT00025181 2014-05-22
Monoclonal Antibody and Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma That Has Been Removed During Surgery
University of Southern California
Phase 1 Completed
NCT00037037 2013-12-18
Vaccine Therapy With or Without Sargramostim in Treating Patients With High-Risk or Metastatic Melanoma
National Cancer Institute (NCI)
Phase 1 Unknown
NCT00003792 2013-06-26
Vaccine Therapy in Treating Patients With Metastatic Melanoma
National Cancer Institute (NCI)
Phase 1 Completed
NCT00559026 2007-11-16
DTIC-melvacc
Istituto Superiore di SanitÃ
Phase 1 Completed